infecti
diseas
due
microb
high
pathogen
potenti
remain
constant
variabl
threat
human
anim
health
emerg
new
diseas
reemerg
diseas
previous
control
complic
situat
date
infecti
diseas
research
undergon
dramat
progress
understand
diseas
mechan
hostpathogen
interact
focus
increasingli
new
strategi
prevent
therapi
signific
progress
achiev
develop
deliveri
system
protect
heterolog
protein
antigen
veterinari
vaccinolog
landmark
infecti
diseas
research
chemic
synthesi
genom
major
new
field
research
refer
synthet
biolog
date
result
chemic
synthesi
polioviru
phage
genom
express
infecti
virus
molecular
level
evolut
pathogen
mechan
genom
flexibl
account
sever
pathogen
properti
infecti
agent
receiv
increas
attent
bacteri
toxin
addit
threat
human
health
interfer
host
cell
cellular
function
receiv
attent
report
highlight
lectur
present
intern
symposium
threat
infect
microb
high
potenti
strategi
detect
control
erad
juli
germani
meet
organ
german
academi
natur
scientist
leopoldina
deutsch
akademi
der
naturforsch
leopoldina
hall
germani
de
scienc
pari
franc
research
center
infecti
diseas
univers
togeth
scientif
societi
germani
speaker
two
poster
session
cover
mani
aspect
infecti
diseas
includ
polit
social
aspect
molecular
cellular
level
action
virul
factor
toxin
potenti
applic
rna
interfer
mechan
genom
flexibl
discuss
reservoir
transmiss
pathogen
novel
detect
method
exploit
mechan
hostpathogen
interact
discuss
develop
novel
prevent
therapeut
approach
comprehens
summari
paper
speaker
invit
oral
present
symposium
publish
soon
seri
nova
acta
leopoldina
http
wwwleopoldinaunihalled
infecti
diseas
biggest
killer
children
young
adult
account
million
death
year
mani
one
two
death
develop
countri
almost
death
communic
diseas
caus
six
diseas
acut
respiratori
diarrhoeal
infect
aid
tuberculosi
malaria
measl
david
l
heymann
geneva
remind
mani
death
occur
result
prevent
diseas
measl
hepat
b
diphtheria
whoop
cough
often
failur
implement
vaccin
program
burden
infecti
diseas
restrict
develop
countri
sinc
previous
control
infecti
diseas
tuberculosi
diphtheria
reemerg
europ
develop
area
world
high
mortal
due
infecti
diseas
alarm
fact
larg
popul
remot
area
develop
world
risk
disabl
diseas
polio
leprosi
lymphat
filariasi
onchocerciasi
report
david
l
heymann
diseas
caus
doubl
econom
burden
reduc
work
forc
undermin
financi
secur
alreadi
impoverish
famili
infecti
diseas
prevent
drug
vaccin
alreadi
avail
inadequ
fund
health
care
develop
countri
inabl
deliv
antimicrobi
drug
antibiot
entir
popul
contribut
devast
situat
tabl
emerg
sever
acut
respiratori
syndrom
sar
one
diseas
newli
identifi
recent
decad
clearli
demonstr
everi
countri
vulner
econom
consequ
exagger
public
fear
unknown
felt
around
world
today
diseas
transport
one
contin
anoth
matter
hour
reason
public
health
care
system
receiv
attent
david
l
heymann
state
global
partnership
strategi
requir
increas
power
epidem
control
realtim
electron
commun
consid
novel
vaccin
strategi
microb
high
pathogen
potenti
one
distinguish
case
biowarfar
newli
emerg
agent
high
pathogen
potenti
consid
latter
case
mass
vaccin
even
vaccin
highrisk
individu
would
unrealist
especi
sinc
overal
risk
side
effect
exceed
risk
diseas
rapid
protect
individu
risk
given
high
prioriti
caus
variou
problem
includ
rapid
diagnosi
well
prompt
induct
highli
efficaci
host
respons
naiv
infect
individu
addit
prompt
chemotherapi
therefor
classic
vaccin
strategi
need
complement
gener
vaccin
strategi
immunomodulatori
intervent
strategi
must
includ
innat
acquir
immun
present
stefan
h
e
kaufmann
maxplanckinstitut
infect
biolog
mpi
berlin
suggest
follow
vaccin
strategi
intracellular
bacteria
deserv
consider
attenu
viabl
strain
ii
nake
dna
encod
protect
antigen
iii
protect
antigen
express
recombin
viabl
vector
bacteria
virus
extracellular
bacteria
control
antibodi
typic
opson
antibodiesand
henc
vaccin
strategi
base
kill
vaccin
subunit
vaccin
protect
intracellular
bacteria
depend
tlymphocyt
rather
antibodi
winau
et
al
although
recent
advanc
genom
basic
immunolog
molecular
biolog
provid
guidelin
construct
novel
vaccin
candid
research
program
involv
stretch
basic
scienc
appli
field
studi
werner
goebel
microbiolog
germani
highlight
develop
live
virulenceattenu
bacteria
deliveri
system
protect
heterolog
protein
antigen
two
differ
strategi
use
one
allow
releas
antigen
gramneg
bacteri
carrier
via
type
secret
system
gentschev
et
al
one
introduc
antigendetermin
plasmid
dna
rna
mammalian
cell
includ
antigenpres
cell
via
intracellular
bacteria
dietrich
et
al
pilgrim
et
al
schoen
et
al
selfdestruct
variant
gramposit
bacterium
listeria
monocytogen
activ
phagederiv
lysin
lyse
upon
intern
use
effici
releas
dna
mrna
cytosol
host
cell
pilgrim
et
al
schoen
et
al
submit
transfer
dna
rna
highli
effici
epitheli
fibroblast
cell
line
also
phagocyt
includ
dendrit
cell
ahemolysin
hlya
secret
system
e
coli
exploit
deliv
heterolog
antigen
hlya
genet
fuse
almost
protein
antigen
without
drastic
affect
secret
eg
virulenceattenu
salmonella
strain
includ
typhi
gentschev
et
al
exploit
type
iii
autotransport
secret
system
gramneg
bacteria
recombin
vaccin
deliveri
cytosol
mammalian
cell
recent
demonstr
b
rizo
et
al
werner
goebel
emphas
approach
might
use
combat
infecti
diseas
might
also
open
new
avenu
antitumor
therapi
either
design
antitumor
vaccin
deliv
therapeut
agent
infect
anim
major
econom
factor
anim
husbandri
also
high
impact
reservoir
human
pathogen
veterinari
vaccin
costeffici
easi
administ
efficaci
within
short
period
time
prefer
one
immun
impli
rather
exclus
relianc
live
vaccin
fox
rabi
major
threat
human
health
serv
exampl
initi
swiss
research
oral
immun
schedul
devis
initi
base
use
bait
compos
chicken
head
fill
blister
contain
liveattenu
rabi
vaccin
steck
et
al
research
led
develop
industri
produc
bait
case
attract
enough
eaten
fox
schneider
bait
distribut
larg
area
erad
rabi
drastic
reduc
incid
sever
european
countri
et
al
success
oral
immun
rabi
fox
follow
similar
approach
classic
swine
fever
csf
wild
boar
csf
highli
contagi
diseas
high
pathogen
potenti
contain
within
european
countri
elimin
pig
infect
hold
sporad
occurr
csf
domest
pig
epidemiolog
link
wild
boar
therefor
elimin
csf
viru
wild
boar
popul
major
prerequisit
protect
domest
pig
farm
cornbas
bait
contain
blister
fill
liveattenu
csfv
cstrain
vaccin
elimin
csfv
quit
common
german
wild
boar
popul
kaden
et
al
veterinari
vaccinolog
recent
achiev
spectacular
success
introduc
first
genet
engin
live
viral
vaccin
marker
technolog
abl
differenti
infect
vaccin
anim
diva
marker
concept
thoma
c
mettenleit
friedrichloefflerinstitut
insel
riem
germani
illustr
success
diseas
control
appli
diva
concept
diva
concept
van
oirschot
success
employ
elimin
aujeszki
diseas
ad
pig
caus
alphaherpesviru
pseudorabi
viru
prv
mettenleit
base
initi
find
sever
liveattenu
prv
vaccin
strain
lack
major
surfac
antigen
glycoprotein
e
ge
invari
present
field
strain
mettenleit
et
al
simpl
elisa
system
develop
abl
specif
detect
presenc
absenc
antig
antibodi
anim
van
oirschot
et
al
base
concept
erad
program
allow
use
gedelet
marker
vaccin
combin
serosurveil
use
detect
antig
antibodi
use
approach
germani
declar
free
ad
februari
et
al
import
mention
ad
erad
campaign
genet
modifi
live
vaccin
use
first
time
europ
wide
scale
similar
erad
program
recent
start
elimin
bovin
herpesviru
infect
cattl
beer
et
al
kaashoek
et
al
kaashoek
et
al
less
complex
rna
virus
gener
specifi
protein
product
like
glycoprotein
e
prv
therefor
requir
differ
diva
approach
scahaw
scientif
committe
anim
health
anim
welfar
diva
concept
also
applic
control
footandmouthdiseas
viru
fmdv
picornaviru
genu
aphthoviru
four
viral
encod
structur
protein
present
within
matur
virion
wherea
infect
cell
anim
nonstructur
protein
also
act
antigen
thu
infect
anim
produc
antibodi
structur
nonstructur
protein
wherea
anim
vaccin
inactiv
virion
produc
antibodi
virion
compon
recombin
swine
fever
viru
csfv
vaccin
de
smit
antigenet
differ
e
glycoprotein
bovin
viral
diarrhea
viru
induc
excel
protect
csfv
challeng
reimann
et
al
likewis
diva
strategi
base
differenti
detect
antibodi
heterolog
neuraminidas
avian
influenza
exampl
present
thoma
c
mettenleit
illustr
success
diva
concept
costeffici
control
eventu
elimin
specif
infecti
agent
livestock
virgin
popul
particularli
threaten
unintent
intent
reintroduct
erad
pathogen
variola
viru
releas
smallpox
viru
viru
success
erad
would
catastroph
sinc
popul
suscept
diseas
nobodi
age
year
ever
vaccin
fenner
et
al
last
natur
case
smallpox
occur
somalia
routin
vaccin
program
stop
vaccin
produc
ceas
make
vaccin
approxim
million
die
diseas
prior
erad
erad
strategi
compris
widespread
vaccin
least
popul
surveil
earli
detect
case
control
outbreak
smallpox
viru
offici
still
exist
two
laboratori
one
atlanta
georgia
usa
one
novosibirsk
russia
possibl
unoffici
other
laboratori
research
continu
former
deputi
director
soviet
union
biolog
weapon
program
declar
smallpox
would
develop
weapon
annual
stockpil
ton
variola
viru
would
maintain
alibek
handelman
bioterror
consider
dampen
hope
posit
medic
econom
benefit
result
global
erad
diseas
present
reinhard
kurth
robertkoch
institut
berlin
germani
ask
whether
realli
erad
infecti
diseas
develop
new
vaccin
improv
old
vaccin
face
challeng
clinic
efficaci
new
vaccin
test
human
rosenth
et
al
sideeffect
old
one
accept
commun
countri
howev
vaccin
depend
other
case
emerg
report
donald
l
henderson
john
hopkin
center
civilian
biodefens
studi
baltimor
usa
poliomyel
diseas
worldwid
current
serious
target
erad
possibl
success
number
case
decreas
case
countri
case
six
countri
although
major
region
polioviru
human
enteroviru
picornavirida
alreadi
elimin
rasch
et
al
global
erad
campaign
danger
african
countri
econom
reason
reduc
vaccin
campaign
achiev
polio
elimin
termin
led
increas
suscept
person
nineti
percent
polio
infect
asymptomat
transmiss
therefor
easili
occur
without
detect
even
new
outbreak
high
risk
problem
present
africa
sudden
new
case
seen
mani
year
poliofre
new
problem
aris
posterad
period
includ
pose
new
threat
bioterror
live
attenu
viru
use
vaccin
transmit
recombin
enterovirus
like
ccluster
coxsacki
virus
result
vaccin
viru
vaccinederiv
polioviru
vdpv
increas
virul
transmiss
longterm
circul
vdpv
past
occur
countri
suboptim
oral
polio
vaccin
opv
vaccin
rate
kew
et
al
occur
independ
egypt
hispaniola
philippin
madagascar
live
attenu
sabin
opv
develop
minim
circul
vaccin
virus
eg
immunodefici
unvaccin
individu
essenti
initi
earli
synchron
stop
live
attenu
sabin
opv
vaccin
maclennan
et
al
confirm
global
erad
individu
countri
stop
vaccin
switch
use
inactiv
salk
polio
vaccin
ipv
least
countri
ipv
produc
manufactur
maintain
larg
quantiti
wildtyp
viru
correspond
seed
viru
stock
even
cessat
vaccin
essenti
conserv
wildtyp
viru
case
emerg
fall
back
vaccin
henderson
problem
contain
wildtyp
polioviru
would
reduc
product
ipv
could
success
base
strain
deriv
sabin
vaccin
viru
sipv
doi
et
al
basic
mechan
polioviru
pathogenesi
still
obscur
true
replic
polioviru
gastrointestin
tract
oral
infect
mechan
viru
spread
central
nervou
system
cn
anoth
mysteri
cun
prefer
viru
destroy
motor
neuron
cn
especi
spinal
cord
specif
lead
paralysi
possibl
deathpoliomyel
major
determin
polioviru
pathogenesi
receptor
koik
et
al
mendelsohn
et
al
analysi
human
primat
specimen
gastrointestin
tract
reveal
strong
express
enterocyt
follicularassoci
epitheli
cell
mcell
peyer
patch
pp
repres
import
site
replic
first
stage
infect
minor
iwasaki
et
al
endotheli
cell
interfollicular
region
pp
also
found
express
observ
leav
open
possibl
polioviru
may
enter
bloodstream
via
vessel
damag
tissu
iwasaki
et
al
entri
cn
occur
passag
bloodbrain
barrier
neuromuscular
junction
follow
retrograd
axon
transport
motor
neuron
cell
bodi
latter
rout
cn
invas
provoc
poliomyel
eg
injuri
enhanc
diseas
progress
gromeier
wimmer
cargo
protein
dynein
motor
discov
affin
ctermin
intracellular
domain
therefor
new
model
retrograd
transport
propos
viru
intern
neuromuscular
junction
transport
cell
bodi
motor
neuron
cargo
vesicl
along
axon
microtubul
driven
dynein
motor
complex
chemic
synthesi
polioviru
absenc
natur
templat
cello
et
al
indic
viru
longer
consid
extinct
genom
sequenc
known
poliovirusspecif
doublestrand
dna
cdna
assembl
synthet
desoxyoligonucleotid
transcrib
enzym
bacteriophag
rna
polymeras
yield
polioviru
rna
rna
ident
genom
rna
nucleotid
except
end
cello
et
al
van
der
werf
et
al
sequenc
synthet
polioviru
spv
cdna
design
contain
silent
mutat
ident
marker
cello
et
al
spv
rna
incub
cellfre
extract
uninfect
hela
cell
direct
viru
specif
translat
genom
replic
virion
assembl
molla
et
al
via
synthet
cdna
outsid
live
cell
gener
polio
viru
plaqu
phenotyp
similar
occur
natur
spv
grow
tumor
cell
highli
attenu
att
transgen
mice
cello
et
al
first
biolog
activ
cdna
synthes
rna
phage
qb
taniguchi
et
al
landmark
accomplish
herald
birth
revers
genet
virolog
contrast
cello
et
al
synthes
viru
chemic
inform
natur
occur
rna
requir
templat
enzymat
reaction
prepar
qb
cdna
fundament
differ
proof
principl
far
reach
consequ
state
eckard
wimmer
stoni
brook
ny
usa
chemic
synthesi
genom
virus
bacteria
longer
dream
research
refer
synthet
biolog
alreadi
becom
new
hot
field
consequ
paper
smith
et
al
describ
synthesi
chemic
mixtur
phage
bp
long
week
reprogram
microorgan
exist
function
modul
lego
biolog
may
yield
novel
microb
capabl
function
highli
specif
effici
minifactori
ferber
genet
flexibl
phenomenon
account
pathogen
properti
mani
infecti
agent
therefor
one
focu
genom
research
character
mechan
involv
genom
variabl
evolut
bacteri
pathogen
new
type
genom
entiti
known
pathogen
island
shown
contribut
rapid
evolut
bacteri
pathogen
horizont
gene
transfer
review
see
dobrindt
et
al
anoth
flexibl
genet
element
repres
integron
first
identifi
primari
mechan
antibiot
resist
gene
captur
dissemin
among
gramneg
bacteria
studi
yersinia
bartonella
shown
numer
gene
rearrang
massiv
gene
inactiv
loss
gene
function
least
import
determin
pathogen
gene
acquisit
siv
ge
andersson
uppsala
sweden
present
deterior
aproteobacteri
human
pathogen
genom
could
mean
elimin
thousand
gene
shift
bacteri
lifestyl
intracellular
anim
environ
vectormedi
transmiss
pathway
comput
approach
use
infer
ancestr
gene
set
quantifi
flux
gene
along
branch
aproteobacteri
speci
tree
boussau
et
al
analysi
suggest
rickettsia
wolbachia
repres
earliest
diverg
lineag
tree
follow
caulobact
boussau
et
al
analysi
indic
loss
gene
prior
diverg
rickettsia
wolbachia
follow
anoth
loss
gene
prior
associ
emerg
typhu
pathogen
r
conorii
contain
gene
present
r
prowazekii
caus
agent
epidem
typhu
eighti
percent
gene
orphan
identifi
speci
genom
analysi
suggest
massiv
loss
gene
immedi
prior
diverg
bartonella
brucella
follow
yet
anoth
major
loss
gene
prior
diverg
b
hensela
b
quintana
genom
sequenc
louseborn
b
quintana
compris
bp
zoonot
agent
b
hensela
compris
bp
alsmark
et
al
genom
comparison
elucid
high
degre
overal
similar
two
genom
b
quintana
b
hensela
caus
trench
fever
catscratch
diseas
respect
uniqu
among
bacteria
abil
induc
tumorlik
lesion
skin
bacillari
angiomatosi
well
liver
spleen
bacillari
peliosi
immunocompromis
individu
transmit
insect
vector
use
mammalian
reservoir
infect
similar
cell
type
howev
b
quintana
specialist
use
human
reservoir
wherea
b
hensela
promiscu
differ
gene
content
mainli
due
presenc
sever
genom
island
b
hensela
present
b
quintana
around
uniqu
gene
b
hensela
attribut
prophag
region
kb
three
genom
island
kb
respect
prophag
evolutionari
mosaic
gene
differ
origin
interspers
gene
show
sequenc
similar
put
phage
wolbachia
potenti
virul
featur
locat
b
hensela
genom
island
multipl
copi
hecb
fhab
put
code
hemolysin
transport
filament
hemagglutinin
respect
two
protein
form
twopartn
secret
system
hecb
gene
product
may
mediat
transport
filament
hemagglutinin
requir
attach
host
cell
alsmark
et
al
largest
uniqu
island
b
quintana
kb
contain
gene
sequenc
similar
yopp
yersinia
enterocolitica
yopj
yersinia
pseudotuberculosi
sequenc
b
quintana
locat
posit
correspond
island
b
hensela
contain
remnant
phage
island
gene
suggest
present
common
ancestor
two
speci
total
siv
ge
andersson
group
identifi
pseudogen
extens
degrad
gene
sequenc
b
hensela
includ
tandem
duplic
remnant
compar
fragment
gene
b
quintana
rearrang
flank
island
uniqu
present
b
hensela
indic
link
rearrang
insertiondelet
event
remnant
gene
present
b
hensela
island
identifi
breakpoint
posit
b
quintana
report
siv
g
e
andersson
two
bartonella
genom
contain
numer
scar
put
phage
plasmid
integr
indic
exposur
genet
parasit
evolutionari
past
howev
human
pathogen
specialist
b
quintana
lost
sequenc
seem
longer
accumul
genet
parasit
thu
two
human
pathogen
specialist
r
prowazekii
b
quintana
experienc
enhanc
frequenc
genom
degrad
compar
closest
rel
hostvector
reproduct
strategi
interestingli
high
pathogen
potenti
yersinia
pesti
sole
attribut
presenc
two
addit
plasmid
shown
elisabeth
carniel
institut
pasteur
pari
compar
analysi
ancestor
pseudotuberculosi
reveal
chromosom
gene
addit
plasmid
repres
new
genet
materi
pesti
contrast
pseudogen
gene
absent
pesti
detect
indic
mani
pseudotuberculosi
gene
longer
function
pesti
chain
et
al
appear
loss
function
least
import
gene
acquisit
evolut
pesti
high
genet
variabl
particularli
danger
pathogen
origin
anim
reservoir
exampl
pandem
influenza
zoonot
diseas
caus
transfer
influenza
virus
viru
gene
segment
aquat
bird
reservoir
human
domest
anim
natur
reservoir
virus
evolutionari
stasi
equilibrium
natur
host
caus
diseas
transfer
new
host
evolv
rapidli
pose
constant
threat
human
anim
health
told
robert
g
webster
st
jude
children
research
hospit
memphi
usa
widespread
infect
poultri
virus
asia
caus
increas
concern
subtyp
form
basi
humantohuman
spread
interspeci
transmiss
multipl
opportun
success
mammalian
transmiss
influenza
virus
provid
continu
evolut
asia
propens
reassort
gener
multipl
genotyp
virus
matrosovich
et
al
antigen
drift
ha
gene
virus
acquisit
high
pathogen
aquat
bird
opportun
reassort
human
influenza
strain
occur
likelihood
success
transmiss
human
high
marburg
ebola
virus
famili
filovirida
reemerg
period
unknown
anim
reservoir
caus
sever
hemorrhag
fever
human
nonhuman
primat
disturb
blood
tissu
barrier
primarili
control
endotheli
cell
immun
suppress
seem
key
pathogen
factor
diseas
report
heinz
feldmann
nation
microbiolog
laboratori
winnipeg
canada
endothelium
affect
two
way
directli
viru
infect
lead
activ
lytic
replic
indirectli
mediatorinduc
inflammatori
respons
mediat
origin
virusactiv
cell
mononuclear
phagocyt
system
primari
target
cell
immun
suppress
may
result
lytic
infect
circul
sessil
cell
mononuclear
phagocyt
system
inactiv
neutrophil
secret
viral
protein
necrosi
antigenpres
cell
lymphoid
deplet
addit
virion
structur
protein
identifi
interferon
antagonist
basler
et
al
despit
clearli
immunosuppress
good
evid
protect
immun
filoviru
hemorrhag
fever
contrast
survivor
asymptomat
case
show
igm
igg
antibodi
respons
viral
antigen
fatal
infect
usual
end
high
viremia
littl
evid
humor
immun
respons
neutral
antibodi
direct
transmembran
glycoprotein
respons
viru
entri
howev
infectivityenhanc
antibodi
direct
transmembran
glycoprotein
also
describ
transmembran
glycoprotein
use
provok
protect
immun
respons
anim
model
includ
nonhuman
primat
sever
distinct
approach
includ
dna
vaccin
replicationdefici
replicationcompet
recombin
virus
achiev
thu
transmembran
glycoprotein
serv
promis
vaccin
candid
filovir
hemorrhag
fever
feldmann
et
al
yellow
fever
viru
lassa
viru
arenaviru
zoonot
virus
caus
clinic
appar
infect
per
year
west
africa
carri
mortal
transmiss
epidemiolog
immunolog
rodentborn
lassa
fever
differ
mosquitoborn
yellow
fever
current
reemerg
diseas
influenc
likewis
ecolog
viral
reservoir
well
immun
suscept
human
popul
herd
immun
yellow
fever
viru
achiev
massvaccin
gener
fade
sinc
immun
program
discontinu
humor
crossimmun
due
heterolog
flaviviru
infect
mitig
sever
diseas
prevent
yellow
fever
epidem
threaten
urban
center
west
africa
vaccin
ever
develop
mainli
tcellcontrol
lassa
viru
outbreak
diseas
rare
focal
restrict
contact
infect
rodent
west
africa
migrat
suscept
human
popul
sever
chang
habitat
rodent
reservoir
led
increas
transmiss
viru
export
lassa
fever
case
european
countri
j
ter
meulen
institut
virolog
univers
marburg
germani
flaviviru
famili
compris
differ
virus
transmit
vertebr
host
mosquito
tick
sever
flavivirus
import
human
pathogen
includ
yellow
fever
dengu
japanes
enceph
west
nile
tickborn
enceph
virus
proven
characterist
newli
emerg
pathogen
point
franz
x
heinz
institut
virolog
medic
univers
vienna
austria
enorm
progress
made
recent
year
elucid
molecular
structur
flavivirus
greatli
enhanc
understand
specif
function
entri
assembl
viral
pathogen
antigen
relationship
immunogen
tickborn
enceph
viru
endem
mani
european
countri
larg
part
asia
includ
northern
china
northern
japan
three
close
relat
subtyp
discern
european
siberian
far
eastern
circul
natur
foci
differ
mammalian
speci
tick
mainli
ixod
ricinu
ixod
persulcatu
human
infect
accident
play
role
maintain
natur
cycl
viru
viru
geograph
distribut
natur
foci
remark
stabl
exhibit
rel
littl
variat
suggest
rel
evolutionari
stasi
viru
delic
balanc
environment
factor
requir
mainten
natur
highli
purifi
formalininactiv
whole
viru
vaccin
widespread
use
europ
proven
excel
mean
prevent
tickborn
enceph
human
recent
introduct
west
nile
viru
northern
america
dramat
exampl
potenti
flavivirus
conquer
new
territori
within
short
period
time
although
viru
sporad
occur
europ
also
caus
rare
infect
human
never
abl
establish
endem
similar
occur
america
viru
appar
found
ideal
ecolog
condit
mainten
spread
far
human
vaccin
yet
commerci
avail
test
human
trial
four
type
dengu
virus
caus
sever
form
dengu
fever
hemorrhag
fever
shock
syndrom
pose
enorm
health
threat
tropic
subtrop
countri
around
globe
sever
form
diseas
appar
promot
secondari
infect
certain
dengu
viru
type
immunolog
enhanc
phenomena
trigger
preexist
immun
differ
type
phenomenon
sever
hamper
develop
dengu
vaccin
concern
vaccin
could
induc
similar
immunopatholog
state
vaccin
individu
bacteri
toxin
repres
import
highli
efficaci
virul
determin
pathogen
therefor
threat
human
health
connect
infecti
diseas
bradberri
et
al
oloughlin
robinsbrown
elucid
mode
action
toxin
import
understand
pathogen
help
prevent
treat
diseas
karmali
substanti
progress
made
elucid
mechan
bacteri
toxin
tetanu
botulinum
anthrax
shiga
toxin
invad
cell
interfer
vital
cellular
function
kirsten
sandvig
institut
cancer
research
norwegian
radium
hospit
oslo
introduc
pathway
use
shiga
toxin
bacteri
shiga
toxin
produc
shigella
dysenteria
shigalik
toxin
stx
produc
escherichia
coli
cholera
toxin
vibrio
cholera
certain
plant
toxin
ricin
act
cell
entri
enzymat
activ
part
molecul
cytosol
gener
toxin
one
moieti
bind
cell
surfac
receptor
anoth
enzymat
activ
moieti
enter
cytosol
exert
action
toxin
studi
toxin
entri
cell
also
provid
us
basic
knowledg
endocytosi
mechan
intracellular
transport
membran
transloc
protein
cell
iversen
et
al
lauvrak
et
al
llorent
et
al
shiga
toxin
first
molecul
found
move
way
cell
surfac
endosom
retrograd
golgi
apparatu
er
sandvig
et
al
similar
traffick
shown
also
toxin
cholera
toxin
ricin
other
hand
number
protein
toxin
travel
much
shorter
distanc
transloc
cytosol
sandvig
endocytosi
mediat
via
clathrindepend
independ
mechan
experi
ricin
indic
endocytosi
independ
lipid
raft
even
circumst
oper
without
gtp
hydrolysi
gar
et
al
shiga
toxin
also
enter
cell
clathrinindepend
mechan
lauvrak
et
al
nichol
et
al
saintpol
et
al
howev
fraction
toxin
exploit
differ
pathway
like
celltyp
depend
similarli
cholera
toxin
endocytos
differ
mechan
shogomori
futerman
singh
et
al
torgersen
et
al
probabl
celltypedepend
differ
exist
shiga
toxin
ricin
seem
transport
earli
endosom
process
either
directli
golgi
via
perinuclear
recycl
compart
iversen
et
al
johann
goud
sannerud
et
al
shiga
toxin
impli
transport
clathrin
requir
effici
endosometogolgi
transport
johann
goud
lauvrak
et
al
saintpol
et
al
molecul
requir
ricin
transport
iversen
et
al
arriv
transgolgi
network
toxin
transport
er
neither
shiga
toxin
ricin
contain
kdel
sequenc
could
facilit
retrograd
transport
kdel
receptor
copico
vesicl
kdel
receptordepend
transport
shown
pseudomona
exotoxin
jackson
et
al
case
shiga
toxin
evid
copiindepend
pathway
detail
known
johann
goud
sannerud
et
al
summari
kirsten
sandvig
indic
work
requir
understand
retrograd
transport
answer
import
might
help
exploit
toxin
medic
therapi
despit
signific
progress
made
control
infecti
diseas
understand
diseas
mechan
special
emphasi
molecular
level
face
date
sever
new
threat
due
infecti
agent
vaccin
program
aim
erad
high
pathogen
microorgan
high
mortal
rate
nevertheless
emerg
newli
identifi
diseas
sar
reemerg
diseas
becom
great
public
health
concern
worldwid
threat
dramat
increas
antimicrobi
resist
pathogen
antimicrobi
resist
antibiot
drug
deadli
impact
control
diseas
tuberculosi
malaria
cholera
dysenteri
pneumonia
basi
control
infecti
diseas
epidem
instal
worldwid
access
commun
platform
public
health
care
system
interchang
storag
current
knowhow
experi
success
employ
erad
program
diseas
treatment
requir
combat
infecti
diseas
landmark
modern
molecular
microbiolog
combinatori
chemistri
chemic
synthesi
microorgan
provid
possibl
construct
novel
deliveri
system
vaccin
may
also
lead
improv
understand
key
molecul
event
develop
diseas
hand
socal
lego
biolog
may
repres
tool
bioterror
term
construct
infecti
agent
high
pathogen
potenti
microbi
evolut
genom
variabl
accompani
horizont
gene
transfer
howev
novel
studi
indic
gene
acquisit
also
loss
gene
function
repres
import
determin
pathogen
compar
genom
analysi
microorgan
special
emphasi
intracellular
pathogen
provid
insight
whether
evolut
microorgan
also
associ
genom
reduct
gene
loss
result
highli
specifi
pathogen
potenti
develop
vaccinolog
veterinari
medicin
highlight
potenti
applic
vaccin
research
success
diseas
control
anim
veterinari
vaccin
campaign
offer
new
perspect
implement
vaccin
program
lowor
middleincom
countri
even
bioterror
attack
veterinari
vaccin
costeffici
easi
administ
efficaci
within
short
period
time
singl
immun
prefer
reach
maintain
high
vaccin
rate
novel
vaccin
fulfil
requir
vaccin
ideal
base
live
vaccin
use
veterinari
vaccinolog
instead
prefer
oral
immun
subunit
vaccin
novel
antigendeliveri
system
implement
order
reduc
burden
infecti
diseas
worldwid
